Kornimate/medical-research-clean huggingface dataset:
translational assessment of vitiligo according to body locations

Conditions: Vitiligo

Summary: vitiligo affects 0.5 to 2% of worldwide population and has a demonstrated impact on the quality of life. optimal treatment of vitiligo requires to target the auto-immune inflammatory response (to halt the depigmentation process), but also to induce the differentiation of melanocyte stem cells (to induce repigmentation). there is a well demonstrated discrepancy in the repigmentation response between anatomical areas of the body. face and neck are the best responder with complete or almost complete repigmentation achieved in most cases under treatment. trunk and limbs could have a complete or almost complete repigmentation in approximately half of the cases. the repigmentation is much more difficult in wrists, elbows, knees, proximal part of the hands. finally, some areas such as the extremities of hands and feet, palms, soles, are almost impossible to repigment. the investigator hypothesize that there are some factors that are produced in the skin that prevent (or at least decrease) the differentiation but also probably the migration and proliferation of melanocytes. primary objective to compare the mrna expression of each types of cells in the skin of vitiligo patients compared to healthy volunteers according to body locations


Eligibility criteria:
inclusion criteria: * men and women with non-segmental vitiligo for the vitiligo group and men and women without any auto-immune disorder for the control group * ≥ 18 and \<70 years * for women of child-bearing age, a urine pregnancy test (βhcg in urines) will be performed. * affiliation to a social security system * signed informed consent exclusion criteria: * pregnant women * segmental or mixed vitiligo * vitiligo with less than 2 years duration * skin auto-immune or inflammatory skin disorders other than vitiligo (ie. active atopic dermatitis, psoriasis, lichen planus...) * exposure to sun (with intent to tan or repigment the skin) or artificial uv (uv cabins, lamps or lasers) during the month before inclusion * concomitant use of topical or systemic immunosuppressive medication or steroids * contra-indication to xylocaine with 2 % adrenalin * pregnant or breast-feeding women * vulnerable people: minors, adult under guardianship or deprived of freedom, adult under curatorship * participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
a phase i study of cetuximab in combination with gefitinib in patients with advanced/metastatic non-small cell lung cancer

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the purpose of this study is to find a safe and effective dose of erbitux and iressa for subject with non small cell lung cancer.


Eligibility criteria:
inclusion criteria: * subjects with advanced or metastatic non small cell lung cancer. * subjects should have had at least one prior chemotherapy with a platinum based therapy. exclusion criteria: * subjects are excluded from this study if they do not have non small cell lung cancer that is advanced or metastatic or have not had at least one prior platinum based chemotherapy.
anti-vegf therapy for subfoveal hemorrhage in patients with neovascular age-related macular degeneration

Conditions: Submacular Hemorrhage; Wet Macular Degeneration; Neovascular Age-related Macular Degeneration

Summary: this study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-vegf treatment in patients with neovascular age-related macular degeneration (nvamd).

the purpose of this study is to define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-vascular endothelial growth factor (anti-vegf) treatment, thereby providing guidance as to when it is reasonable to treat with anti-vegf and when it is necessary to displace the hemorrhage in addition to treating with anti-vegf. this is a prospective study that will enroll 98 patients with subretinal hemorrhage in the fovea \[also known as subfoveal hemorrhage (sfh)\] secondary to neovascular amd at the wilmer eye institute, johns hopkins hospital (downtown campus and all other eye care network clinics). the primary endpoint is at month 12 and the secondary endpoint is at month 24. the duration of the study is 24 months. study visits will include a baseline visit, then monthly visits for 12 months, followed by standard care treatment visits in the second year until month 24. the patients will be stratified into two groups based on standard of care management: 1. patients receiving intravitreal (ivt) anti-vegf injections; 2. patients undergoing sfh displacement followed by ivt anti-vegf injections. patients will receive monthly anti-vegf injection for 12 months, followed by anti-vegf at standard of care treatment interval during months 12-24; or sfh displacement (at investigators' discretion) followed by monthly ivt anti-vegf injections for 12 months, and standard of care treatment interval during months 12-24.

Eligibility criteria:
inclusion criteria: * signed informed consent and authorization of use and disclosure of protected health information * age 50 years or older * presence of subretinal hemorrhage (srh) involving the fovea in patients with nvamd including polypoidal choroidal vasculopathy (pcv) exclusion criteria: * sfh in the study eye due to causes other than nvamd * media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging * substantial loss of va due to condition other than amd * limited visual potential from substantial atrophy or fibrosis in fovea * poor visual potential with known permanent reduction in visual acuity prior to sfh

Keywords: nvamd anti-vegf
tailored therapeutic model according to the expression of genes in inflammatory bowel disease patients

Conditions: Inflammatory Bowel Diseases

Summary: this study is a randomized controlled study conducted at five tertiary university hospitals. patients who are 20-80 years old, diagnosed as having inflammatory bowel disease(ibd) and who are planned to start thiopurines for the first time for the treatment of ibd are enrolled. patients are assigned to the genotyping group or to the non-genotyping group. the patients who carry any heterozygotic variant among the three genes receive 50 mg azathioprine (aza) or 25 mg of 6-mercaptopurine, while those who have any homozygotic variant are recommended to take other alternative drugs. the patients who do not carry any genetic variant or are assigned in non-genotyping group receive the standard dose of thiopurines based on the conventional approach. patients in the non-genotyping group receive the standard dose of thiopurines based on the conventional approach.


Eligibility criteria:
inclusion criteria: * 20-80 years old * patients who were diagnosed as having ibd based on clinical, endoscopic, radiographic, and histological assessments, * patients who were planned to start thiopurines for the first time for the treatment of ibd. exclusion criteria: * patients who had previous use of thiopurine * those who had abnormal laboratory findings prior to screening, including white blood cell (wbc) count \< 3,000/μl, platelet (plt) count \< 100/μl, or elevation of aminotransferase more than twice the upper normal limits * those who were diagnosed other infectious diseases at the time of screening or receiving antibiotics within the previous 7 days; * those who were pregnant or lactating.
complications and risk factors related with central venous catheters in cancer patients

Conditions: Thrombosis; Infections

Summary: the investigators aim to determine the complications and risk factors related with peripherally inserted central catheters (piccs) and central venous catheters (cvcs) in cancer patients.

the purpose of this study is to determine the complications and risk factors related with peripherally inserted central catheters (piccs) and central venous catheters (cvcs) in cancer patients.

Eligibility criteria:
inclusion criteria: * all adult cancer patients with central venous catheters (cvcs) or peripherally inserted central catheters (piccs) placed at beijinghch. exclusion criteria: * without written informed consent

Keywords: catheters central venous complications cancer
domiciliary physiotherapy during breast cancer radiation

Conditions: Shoulder Pain

Summary: background: breast cancer is the most common type of cancer among women. its treatment, including radiotherapy (rt), can cause potential complications to be treated by the physiotherapy. objective: to evaluate the effect of domiciliary physiotherapy on the upper limb applied during the period of radiotherapy in women submitted to surgical and radiotherapy for breast cancer. study design: this is a prospective randomized controlled clinical trial. methods: thirty six volunteers were recruited from november 2009 to march 2012 and they were appraised at three different times: pre-rt, post-rt and 2 months after the end of rt. the parameters evaluated were: shoulder range of movement (rom) and arm circumference. they were divided into two groups: cg) control group, submitted only to the assessments and sg) study group, submitted to domiciliary physiotherapy.


Eligibility criteria:
inclusion criteria: - having been diagnosed with unilateral breast cancer and having been submitted to surgical and radiation treatment as part of the treatment for breast cancer, according to the therapeutic protocol of the unit exclusion criteria: - patients with neurological or orthopedic diseases that could impair the movements of the upper limbs, bilateral breast cancer, previous thoracic radiotherapy, and the presence of distant metastasis.

Keywords: breast cancer physiotherapy radiotherapy
safety and tolerability of repeated subcutaneous injections of cad 106 in mild alzheimer's patients

Conditions: Alzheimer's Disease

Summary: this study will evaluate the safety and tolerability of repeated subcutaneous injections of cad106 in patients with mid alzheimer's disease


Eligibility criteria:
inclusion criteria: * male and/or female patients between 40 and 85 years of age (both inclusive) * diagnosis of mild alzheimer's disease (ad) * mini-mental state examination (mmse) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks. exclusion criteria: * previously participated in an ad vaccine study and received active treatment. * history or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition. * history or presence of seizures and/or cerebrovascular disease. * presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression) * advanced, severe, progressive or unstable disease that might interfere with the safety of the patient. other protocol-defined inclusion/exclusion criteria may apply

Keywords: active immunization alzheimer's disease antibody vaccine central nervous system diseases neurodegenerative diseases
virtual reality assisted patient empowerment: diagnose attr-amyloidosis and start treatment

Conditions: Amyloidosis Cardiac; Virtual Reality

Summary: attr amyloidosis is a serious condition with significant morbidity and mortality. in germany, there are numerous unreported cases of untreated patients, and diagnosing and initiating treatment often requires multiple specialized tests. to address this, a study is being conducted to determine if virtual reality (vr)-based patient education can improve diagnosis rates, treatment initiation, and medication adherence compared to standard education methods.

tafamidis is effective in reducing mortality and hospitalization in patients with transthyretin amyloid cardiomyopathy (attr-cm), and adherence to the drug is generally high. however, the main challenge lies in timely diagnosis and initiation of therapy. virtual reality (vr) offers an immersive educational tool that surpasses conventional methods like brochures and videos, with patients preferring vr glasses. by preparing patients through vr, they can engage in informed conversations with physicians, understand the diagnostic process better, and be motivated to initiate therapy promptly. vr empowers patients and saves valuable time for physicians, and it has been well-received even among older cardiovascular patients

Eligibility criteria:
inclusion criteria: * patients who present themselves for assessment of an unclear septal thickening with suspicion of cardiac amyloidosis. exclusion criteria: 1. \< 18 years 2. active medication with tafamidis 3. cardiovascular disease 4. highly impaired vision or hearing 5. advanced dementia syndrome 6. epilepsy 7. insufficient language skills

Keywords: attr; cardiac amyloidosis; virtual reality; suspected transthyretin amyloid cardiomyopathy
clinical trial to evaluate the efficacy and safety of d064 and d702 combination therapy versus d064 or d702 monotherapy

Conditions: Essential Hypertension

Summary: the purpose of this study is to evaluate the efficacy and safety of d064 and d702 combination therapy versus d064 or d702 monotherapy in essential hypertension patients

this study is a randomized, double-blind, multi-center, therapeutic confirmatory, phase 3 trial to evaluate the efficacy and safety of d064 and d702 combination therapy versus d064 or d702 monotherapy in essential hypertension patients

Eligibility criteria:
inclusion criteria: 1. subjects who are 19 years old or older. 2. subjects who are mean blood pressure measured in the arm selected as the reference arm meets the following criteria: * didn't take antihypertensive drug * 140 mmhg ≤ mssbp(mean sitting sbp) \< 180 mmhg * taking antihypertensive drug * 130 mmhg ≤ mssbp(mean sitting sbp) \< 180 mmhg 3. subjects who have voluntarily decided to participate in this clinical trial and signed icf. exclusion criteria: 1. subjects with a history of secondary hypertension or suspected secondary hypertension 2. subjects with symptomatic orthostatic hypotension 3. subjects with type 1 diabetes or diabetes that is not adequately controlled (hba1c \> 9.0%) 4. subjects with severe heart failure(nyha class 3,4) etc., 5. subjects with a history of unstable angina, moderate or malignant retinopathy, etc., within 6 months at the time of screening 6. subjects with a history of disability to investigational product adme at the time of screening 7. subjects with abnormalities in laboratory test results at the time of screening 8. subjects with hypersensitivity or history of investigational product and similar drugs 9. subjects who are required to administer a combination of prohibited drugs specified in this plan during the clinical trial participation period 10. subjects with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening 11. subjects who received other investigational product within 4 weeks of screening visit 12. pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last investigational product 13. subjects who are unable to participate in this clinical trial at the discretion of the investigator
efficacy of patient management for lymphoma diagnosed at nimes university hospital from 1999 to 2018. dvr-lym-nim

Conditions: Lymphoma, Malignant

Summary: observation of a cohort of 400 patients with different types of lymphomas.

a database on 400 patients diagnosed with lymphomas was built up over 20 years at nîmes university hospital. biopsies were made on these tumours and all the samples were frozen. considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. however, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results. the analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment. the aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.

Eligibility criteria:
inclusion criteria: * patients over the age of 15 years and 3 months, diagnosed with lymphoma at nîmes university hospital as from 1999 onwards and for whom diagnostic tumor material is available. exclusion criteria: * patients aged 18 or over who have expressed their desire not to take part in the study. * patients under the age of 18 whose legal representatives have expressed their desire for the child not to take part in the study. * patients under legal guardianship.

Keywords: -lymphoma mantle-cell follicular hodgkin t-cell primitive cerebral marginal zone waldenström's macroglobulinemia
abc science collaborative registry study

Conditions: COVID19

Summary: the abc registry is associated with pro00107943 and provides a resource for collecting information on members of school communities both regionally in north and south carolina, as well as nationally in the united states (u.s.) through the national program, including children, parents, teachers, superintendents, and other staff; and children identified through clinical practice. the overall goals of the registry are to collect data relevant to public health during the coronavirus 2019 (covid-19) pandemic and to establish and engage school communities that may be eligible for participation in future research studies, including observational studies, as well as prospective covid-19 trials.


Eligibility criteria:
inclusion criteria: * participant currently attends, is the parent of a student, works in, or works with a school that is participating in the abc science collaborative, or participant is an adult or child who learned of the registry through clinical practice and is interested in participating in covid-19 related research, * participant or their parent/guardian has provided informed consent or assent, as applicable * participant or their parent/guardian has downloaded the "abc science" app from the app store as a part of the abc science collaborative and has agreed to the app's terms of use * participant or their parent/guardian is able to speak and read english or spanish exclusion criteria: * there are no specific exclusion criteria for this registry. participants must meet inclusion criteria.
study to assess the efficacy and safety of meropenem and pralurbactam in ciai

Conditions: Intra-abdominal Infections

Summary: this is a phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of meropenem and pralurbactam compared with ceftazidime-avibactam in combination with metronidazole in the treatment of adult complicated intra-abdominal infections (ciai).

this is a phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of meropenem and pralurbactam compared with ceftazidime-avibactam in combination with metronidazole in the treatment of adult complicated intra-abdominal infections (ciai). treatment duration for each cohort was 7 to 14 days.

Eligibility criteria:
inclusion criteria: * male or female participants ≥18 and ≤75 years of age. * diagnosed or highly suspected ciai. * evidence of a systemic inflammatory response with at least one of the following:a. fever ( temperature ≥ 38°c); b. hypotension (systolic blood pressure \< 90 mmhg); c. abdominal pain; d. nausea and/or vomiting; e. physical examination found abdominal mass; f. mental state change; g. other circumstances. * female subjects must meet the following conditions: a. menopause for at least 1 year, or b. sterilization has been performed, or c. those who are fertile must meet the following conditions at the same time: the random pre-blood/urine pregnancy test is negative, effective contraceptive measures are taken during the study period and within 30 days after the last application of experimental drugs, and eggs are not donated, and they are not breastfeeding. * male subjects are willing to take effective contraceptive measures and not donate sperm during the study period and within 30 days after the last application of experimental drugs. * understand and abide by the research procedures and methods, voluntarily participate in this research, and sign an informed consent form . exclusion criteria: * allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials. * non-complicated abdominal infection (infection is limited to abdominal organs), such as simple appendicitis and simple cholecystitis. * abdominal wall infection or abscess (infection has not spread into abdominal cavity). * the creatinine clearance rate in the screening period is ≤50ml/min. * the estimated survival time is less than 4 weeks. * those who have a history of drug abuse or drug abuse within 6 months before screening. * those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices. * any physiological or psychological disease or condition that may increase the risk of the experiment, affect the compliance of the subject with the protocol or affect the completion of the experiment as judged by the researcher. * subjects are directly related persons who participated in this research.
role of dexamethasone for erector spinae plane block in patients undergoing total abdominal hysterectomy

Conditions: Postoperative Pain

Summary: the aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone for erector spinae plane block for postoperative analgesia in patients undergoing total abdominal hysterectomy group 1: bupivacaine 0.25% + dexamethasone 8 mg * group 2: bupivacaine 0.25% * group3: control group a prospective randomized interventional double-blind study.

optimal dynamic analgesia is recognized as the key to enhanced recovery following open abdominal surgery. in the last decade, there has been a significant shift away from thoracic epidural analgesia (tea) that has been long considered as the gold standard. various techniques have tried to replicate the analgesic efficacy of tea. they include transversus abdominis plane analgesia (tap), rectus sheath analgesia (rs), wound infusion analgesia (wi) and trans muscular quadratus lumborum analgesia. however, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for all open abdominal surgeries. chin et al first described the erector spinae plane (esp) block for providing analgesia following ventral hernia repair. the unique feature of the ultrasound-guided truncal blocks is that in all of these techniques, in contrast to peripheral nerve blocks, no nerve or plexus needs to be identified: local anesthesia (la) is injected in a particular muscle plane, in which the injectate spreads and reaches the intended nerves. this simple mechanism has made delivery of nerve blocks easy and versatile.

Eligibility criteria:
inclusion criteria: * women ranging age between 30-60 years a who undergoing elective total abdominal hysterectomy exclusion criteria: * participants had known sensitivity to bupivacaine * participants had difficulty in intubation * participants were on chronic pain medication or already on long-term opioids * participants smokers * participants with disabilities who were unable to communicate pain levels * refuse to consent

Keywords: erector spinae plane block total abdominal hysterectomy dexamethasone